共 50 条
[1]
Talbot G.H., Bradley J., Edwards J.E., Et al., Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America, Clin Infect Dis, 42, pp. 657-668, (2006)
[2]
Steenbergen J.N., Alder J., Thorne G.M., Tally F.P., Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections, J Antimicrob Chemother, 55, pp. 283-288, (2005)
[3]
Streit J.M., Jones R.N., Sader H.S., Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram-positive organisms, J Antimicrob Chemother, 53, pp. 669-674, (2004)
[4]
Wise R., Gee T., Andrews J.M., Et al., Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers, Antimicrob Agents Chemother, 46, pp. 31-33, (2002)
[5]
Arbeit R.D., Maki D., Tally F.P., Et al., The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections, Clin Infect Dis, 38, pp. 1673-1681, (2004)
[6]
Lipsky B.A., Stoutenburgh U., Daptomycin for treating infected diabetic foot ulcers: Evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections, J Antimicrob Chemother, 55, pp. 240-245, (2005)
[7]
Shah P.M., lsaacs R.D., Ertapenem, the first of a new group of carbapenems, J Antimicrob Chemother, 52, pp. 538-542, (2003)
[8]
Wexler H.M., In vitro activity or ertapenem: Review of recent studies, J Antimicrob Chemother, 53, SUPPL. S2, pp. 11-21, (2004)
[9]
Nix D.E., Majumdar A.K., DiNubile M.J., Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians, J Antimicrob Chemother, 53, SUPPL. S2, pp. 23-28, (2004)
[10]
Laethem T., De Lepeleire I., McCrea J., Et al., Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers, Antimicrob Agents Chemother, 47, pp. 1439-1442, (2003)